Alaunos Therapeutics
TCRT
146 hedge funds and large institutions have $336M invested in Alaunos Therapeutics in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 58 increasing their positions, 32 reducing their positions, and 16 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 32
51% more call options, than puts
Call options by funds: $5.34M | Put options by funds: $3.54M
39% more capital invested
Capital invested by funds: $242M → $336M (+$94.2M)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0.01% more ownership
Funds ownership: 0.31% → 0.32% (+0.01%)
0% more funds holding
Funds holding: 146 → 146 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$4.94M |
| 2 |
Goldman Sachs
New York
|
+$4.7M |
| 3 |
BlackRock
New York
|
+$4.15M |
| 4 |
Millennium Management
New York
|
+$3.86M |
| 5 |
JP Morgan Chase
New York
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.19M |
| 2 |
Renaissance Technologies
New York
|
-$1.86M |
| 3 |
Two Sigma Investments
New York
|
-$1.28M |
| 4 |
Morgan Stanley
New York
|
-$1.24M |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$930K |
TCRT Hedge Fund Activity: Q2 2020 in Review
146 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2020, worth a combined $336M — up 39% from $242M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TCRT positions and 16 closed out — a net gain of 1 holder — while 58 added to existing stakes and 32 trimmed.
The largest buyer was State Street, adding an estimated $4.94M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $9.19M sold.
- 146 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $336M of Alaunos Therapeutics stock for Q2 2020, up 39% quarter-over-quarter.
- 17 funds opened new Alaunos Therapeutics positions in Q2 2020 and 16 closed out, a net change of +1 holder.
- The largest Alaunos Therapeutics buyer in Q2 2020 was State Street, an estimated $4.94M added.
- The largest Alaunos Therapeutics seller in Q2 2020 was EcoR1 Capital, an estimated $9.19M sold.
Based on aggregated 13F filings for Q2 2020.